The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020. Among them, 191 patients had diagnoses of both asthma and COPD.

These findings re-inforce the growing clinical narrative that eosinophilic inflammation is a key modulator of response to biologic therapies in COPD, echoing similar subgroup-driven efficacy patterns ...

Emphysema is a type of COPD that causes progressively worsening symptoms, including difficulty breathing, wheezing, and coughing. Smoking is the most common cause of the condition.

The success of Dupixent has demonstrated the viability of biologics in COPD. (Image Credits: Pixabay) AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be ...

TUESDAY, Dec. 10, 2024 (HealthDay News) -- Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a ...

(HealthDay News) — Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published ...

Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results ...

Treatment for asthma and COPD exacerbations have not changed in 50 years despite causing 3.8 million deaths worldwide a year combined.” The study is published in The Lancet Respiratory Medicine.

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

In the trial, patients having an asthma or COPD attack were randomly assigned to be treated with benralizumab injection and placebo tablets, standard of care with prednisolone 30mg daily for five days ...